Emerging Therapeutics for Alzheimer's Disease: An Avenue of Hope

Steven C. Samuels, Hillel Grossman

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations

Abstract

Emerging therapies for Alzheimer's disease offer hope to patients and their caregivers. Future treatments will probably include combination approaches with agents that modify amyloid processing, deposition, and clearance. One example, the AD vaccine, reduced amyloid burden and changed behavior in animal models of AD, but the human trial was halted when several subjects developed brain inflammation. Anti-inflammatory agents have epidemiologic support, but clinical trials have been disappointing, possibly related to inadequate study with anti-inflammatory agents that modify amyloid processing. Agents that target known cardiovascular risk factors, such as hypercholesterolemia, hypertension, and insulin resistance, have epidemiologic, preclinical, and clinical evidence to warrant further investigation. Heavy metal chelators, antioxidants, neurotrophic factors, glutaminergic modulators, and agents that modify hyperphosphorylation of Tau are other approaches in research and development.

Original languageEnglish
Pages (from-to)834-845
Number of pages12
JournalCNS Spectrums
Volume8
Issue number11
DOIs
StatePublished - Nov 2003

Fingerprint

Dive into the research topics of 'Emerging Therapeutics for Alzheimer's Disease: An Avenue of Hope'. Together they form a unique fingerprint.

Cite this